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The neonatal Fc receptor (FcRn) is responsible for the recycling and transcytosis of IgG
and albumin. FcRn level was found altered in cancer tissues and implicated in tumor
immunosurveillance and neoplastic cell growth. However, the consequences of FcRn
down-regulation in the anti-tumor immune response are not fully elucidated. By using
the B16F10 experimental lung metastasis model in an FcRn-deficient microenvironment
(FcRn−/− mice), we found lung metastasis associated with an abnormal natural killer (NK)
cell phenotype. In FcRn−/− mice, NK cells were immature, as shown by their surface
marker profile and their decreased ability to degranulate and synthesize interferon γ after
chemical and IL-2 or IL-12, IL-15 and IL-18 activation. These new findings support
the critical role of FcRn downregulation in the tumor microenvironment in anti-tumor
immunity, via NK cell maturation and activation.
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INTRODUCTION
The neonatal Fc receptor (FcRn) is a member of the IgG-Fc receptor family comprising type
I (e.g., “classical” FcγRs) and type II (e.g., non-classical FcR: FcRn, TRIM21) receptors (1–3).
The structure, expression and functions of this IgG-Fc receptors have been extensively rewiewed
regarding their major role in the regulation of immune responses (4). FcRn is an MHC class
I-related molecule consisting of a heavy chain associated with β2-microglobulin molecule, well-
known for its role in regulating IgG and albumin homeostasis (5). Indeed, FcRn-dependent IgG
and albumin recycling leads to an extended half -life of these two molecules (6, 7). FcRn is also
a main actor in the biodistribution of IgG and albumin throughout the body, via transcytosis
(3, 8). Accordingly, FcRn expression is ubiquitous within organs and tissues, with high expression
in endothelial and epithelial cells (9). It is also expressed by hematopoietic cells, in particular
macrophages/monocytes and dendritic cells (DCs) (10). The expression of FcRn in antigen-
presenting cells is connected to its implication in the humoral immune response, via an immune
complex presentation (11).
Besides these functions, FcRn was recently found an important player in anti-tumor immunity.
First, FcRn in immune cells was shown to be critical for the activation of tumor-reactive
CD8+ T cells in colorectal cancer (12). The density of FcRn-expressed DCs was correlated with
CD8+ T-cell number and predicted improved prognosis in human colorectal carcinoma. Second,
we reported FcRnmRNA and protein levels in both lung cancerous tissue and non-cancerous tissue
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associated with favorable prognosis in non-small cell lung cancer
(13). Third, studies involving neoplastic cells expressing different
levels of FcRn showed that FcRn-mediated recycling of albumin
reduced tumor cell growth and proliferation (14).
Because FcRn may shape additional anti-tumor properties,
here we further investigated the consequences of its
downregulation. We used the B16F10 experimental lung
metastasis model (15, 16) in an FcRn-depleted environment
(FcRn−/− mice) and compared the different cellular components
of the anti-tumor immune response in wild-type (WT) and
FcRn−/− mice. We explored natural killer (NK) cells as relaying
FcRn-dependent anti-tumor immunity. These cells are important
in the host and therapy-induced immune response against cancer
(17, 18) and their efficacy in vivo is compromised by suppressive
signals delivered by tumor or tumor-associated cells (19, 20).
MATERIALS AND METHODS
Cell Line
Themurinemelanoma cell line B16F10 Luc+ was a kind gift from
Dr Laurent Gros (Institute of Cancer Research of Montpellier,
Montpellier, France). The murine lymphoma cell line YAC-
1 was purchased from the American Type Culture Collection
(ATCC). B16F10 Luc+ and YAC-1 cells were maintained in
RPMI 1640 culture medium (Sigma-Aldrich) supplemented with
10% heat-inactivated FBS (Lonza), 2mM L-glutamine, 100 U/ml
penicillin and 100µg/ml streptomycin (Sigma-Aldrich) referred
as complete medium.
B16F10 Experimental Lung Metastasis
Model
WT C57BL/6J mice were obtained from Charles River
Laboratories. FcRn−/− C57BL/6J mice, deficient in fcgrt
gene (B6.129X1-Fcgrt tm1 Dcr/DcrJ (fcgrt−/−)], were originally
purchased from The Jackson Laboratory. A targeting vector was
designed to replace 1,588 nucleotide fragments (encoding the
promoter sequence 5′ end of the transcriptional start site, exon
1, intron 2, and most of exon 2) with a PGK-NeoR cassette. The
vector was electroporated into 129X1/SvJ-derived ESV/J-1182
embryonic stem (ES) cells. Correctly targeted ES cells were
injected into recipient C57BL/6J blastocysts. The resulting
chimeric animals were crossed to C57BL/6J mice. The mice
were then backcrossed to C57BL/6J for 11 generations. All mice
were maintained in a dedicated pathogen-free environment
in our animal facility and were used at age 7–12 weeks. All
animal studies were performed according to French national
regulations (EC directive 86/609/CEE, French decree no. 87-848)
after approval was received from the Committee on the Ethics
of Animal Experiments of the Val-de-Loire, CEEA VdL (referral
no. 2015070117414040).
Syngeneic experimental lung metastases were induced by
intravenously injecting 105 B16F10 Luc+ melanoma cells in 100
µl RPMI 1640 medium in the tail vein of WT and FcRn−/−
mice. The cells colonized lungs and formed well-defined black
melanocytic nodules in the lung (15, 21). After 18 days, mice
were euthanized. Lungs and spleens were harvested for further
analysis. Lungs were scored for number of tumor nodules.
Cell Preparation for Flow Cytometry
Lungs were dissociated into single-cell suspensions by combining
mechanical dissociation (gentleMACS Dissociators, Miltenyi)
with enzymatic degradation of the extracellular matrix. The
enzymatic degradation involved use of a digestion buffer:
RPMI 1640 containing 5% FBS, 125µg/ml Liberase LT (Roche
Diagnostics) and 100µg/ml DNAse corresponding to 200 Kuntz
units/ml DNAse (Roche Diagnostics). Spleens were flushed with
a 25G needle and syringe containing the digestion buffer, then
incubated for 30min at 37◦C. Bone-marrow cells were isolated
from the femur and tibia by flushing with a 25G needle and
syringe containing 1X PBS. Red blood cells in the resulting cell
suspensions were lysed by using an ammonium chloride buffer,
then filtered (70µm, MACS SmartStrainers) and resuspended
at 107 cells/ml in 1X PBS containing 5% FBS and 2mM
EDTA.
Murine NK-Cell Isolation And ex vivo
Expansion and Stimulation
NK cells were isolated from pooled spleens of WT or FcRn−/−
mice by negative selection with magnetic Microbeads (NK
cell isolation kit II, Miltenyi). NK-cell purity was >90%.
NK cells were expanded in RPMI 1640 complete medium
supplemented with 5,000 U/ml rhIL2 (PreproTech) for 4 days.
For the cell growth and mortality analyses, cells were counted
daily using a cell counting chamber (Malassez). Cell surface-
mobilized CD107a and intracellular IFN-γ levels were measured
as described (22) after 4-h stimulation with phorbol 12-myristate
13-acetate (PMA, 100 ng/mL) and 500 ng/mL ionomycin calcium
(Sigma-Aldrich) at 37◦C in 5% CO2. Next, 10
5 freshly isolated
NK cells were added per well with 5 µl (0.5 mg/ml) anti-CD107a
(clone 1D4B, FITC, Becton Dickinson [BD]) and 1 µg/106 cells
of brefeldin A (GolgiPlug, BD). At the end of incubation, cells
were washed with 1X PBS containing 5% FBS and 2mM EDTA.
Then, NK cells were treated with an Fc block (anti-CD32/CD16
in the form of 2.4G2 hybridoma culture supernatant) to inhibit
non-specific antibody binding for 20min and stained for surface
NK-cell markers: NK1,1 (clone PK136, APC, BD), NKp46 (clone
29A1.4, Pe, BD), CD27 (clone LG.3A10, PeCy7, BD) and CD11b
(clone M1/70, PerCPCys5.5, BD) for 30min. Samples were fixed
and permeabilized according to the manufacturer’s instructions
(BD) and stained for intracellular IFN-γ (clone XMG1.2, APC-
H7, BD) for an additional 30min. After washing, cells were
analyzed by flow cytometry. For cytokine induced cell surface-
mobilized CD107a and intracellular IFN-γ production, 2 ×
106–5 × 106 freshly isolated splenocytes were seeded in RMPI
1640 complete medium supplemented or not with 5,000 U/ml
rhIL2 or 5 ng/ml rhIL12 (MBL), 50 ng/ml rhIL15 (Miltenyi) and
10 ng/ml rhIL18 (MBL) for 4-h in the presence of brefeldin A
and anti-CD107a. After incubation, the cells were additionally
stained for CD3, NKp46, NK1.1 and IFN-γ flow cytometry
analysis.
Murine NK-Cell Cytotoxicity Assay
For in vitro cytotoxicity assays, isolated NK cells were maintained
overnight in RPMI 1640 complete medium supplemented with
50 U/ml rhIL2 and mixed at indicated effector: target ratios
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(10:1, 5:1 and 1:1) with carboxyfluorescein diacetate succinimidyl
ester (CFSE, TonboBio) labeled target YAC-1 cells as previously
described (23, 24). After 4-h of incubation at 37◦C, the specific
target cell lysis was assessed by flow cytometry (23).
Flow Cytometry
Single-cell suspension prepared from mouse lungs and spleens
were analyzed by flow cytometry (MACSQuant Analyzer
10, Miltenyi). After adding Fc blocking 2.4G2 hybridoma
supernatant, cells were stained with mixtures of monoclonal
antibodies at the optimal concentration determined in our
laboratory and designed to distinguish leukocytes. Mix 1, for
dendritic cells, neutrophils and macrophage/monocytes: CD45
(clone 30-F11, APC-H7, BD), CD11c (clone N418 APC, BD),
CD11b (PErCPCys5.5, BD), Ly6G (clone 1A8, FITC, eBioscience
[eBio]), Ly6C (clone HK1.4, PeCy7, eBio), and F4/80 (clone
BM8, V450, BD). Mix 2, for B and T lymphocytes: CD45,
CD19 and B220 (clone RA3-6B2, APC, BD), CD3 and TCR
(clone H57-597, V450, BD), CD8 (clone 53-6.7, PerCPCys5.5,
BD) and CD4 (clone GK1.5, PeCy7, eBio). Mix 3, for NK cells:
CD45, exclusion of T and B cells (lineage CD3/TCR/CD19/B220,
V450), NKp46 (PE, eBio); and for NK maturation, CD27 (APC,
BD) and CD11b (PErCPCys5.5, BD). For bone-marrow single-
cell suspensions, an exclusive additional mix was used for
NK development: CD45, exclusion of T and B cells (lineage
CD3/TER119/C19/B220, FITC), CD122 (clone TM-beta 1, Pe,
eBio), NK1,1 (PerCPCys5.5, BD), NKp46 (V450, BD), CD11b
(PeCy7, BD), and CD49b (clone DX5, APC, BD). LIVE/DEAD
Fixable Aqua Dead Cell Stain Kit (Invitrogen) was added for
excluding nonviable cells in all analyses. Data analysis involved
use of Kaluza 1.3 flow cytometry analysis software (Beckman
Coulter).
Statistical Analysis
All results are expressed as median ± Min to Max, unless
specified. Statistical significance was analyzed by two-tailed
non-parametric and unpaired Wilcoxon-Mann-Whitney test.
P < 0.05 was considered statistically significant. Statistical
analysis involved use of Prism 5 (GraphPad Software, San Diego,
CA), where, ns= not significant, ∗p≤ 0.05, ∗∗p≤ 0.005 and ∗∗∗p
≤ 0.0001.
RESULTS
Abnormal Immune Cell Profile Associated
With Development of Experimental Lung
Metastasis in Mice Lacking FcRn
To dissect the role of FcRn in anti-tumor immunity, we
used the well-characterized syngeneic B16F10 experimental lung
metastasis mousemodel (15, 16). B16F10 cells were intravenously
injected in WT and FcRn−/− C57BL/6 mice. Macroscopy of
lungs revealed a greater number of pulmonary nodules in
FcRn−/− thanWTmice at 18 days post-implantation (Figure 1).
No nodule was detected in other organs under the experimental
conditions.
To investigate the immune cell populations in lungs of
WT and FcRn−/− mice, we used flow cytometry of cell
FIGURE 1 | Role of neonatal Fc receptor (FcRn) in experimental lung
metastasis development. Wild-type (WT) (n = 14) and FcRn−/− (n = 12) mice
were intravenously injected in the tail vein with 1 × 105 B16-F10 tumor cells in
100 µl medium. 18 days after tumor injection, animals were sacrificed and
lung tumor lesions were blindly counted. (A) Representative photographs of
WT and FcRn−/− lungs after 18 days. (B) Nodule counts in WT and FcRn−/−
mice. Data are expressed as median ± Min to Max from three independent
experiments. ***p ≤ 0.0001 using two-tailed non-parametric and unpaired
Wilcoxon-Mann-Whitney test.
suspensions from fully dissociated lungs to distinguish
leukocyte populations (Supplementary Figure S1). The
proportion of macrophages/monocytes (CD11b+/F4/80+),
B lymphocytes (CD19+/B220+), T lymphocytes (CD3+/TCR+)
and CD4+ T lymphocytes (CD3+/TCR+/CD4+) did not differ
between FcRn−/− and WT mice (Figures 2B–F), but that of
conventional dendritic cells (cDCs: CD11c+/CD11b+) and
CD8+ T lymphocytes (CD3+/TCR+/CD8+) was significantly
lower in FcRn−/− than WT mice (Figures 2A,G). As
well, the percentage of neutrophils (CD11b+/Ly6G+) was
significantly higher in FcRn−/− than WT mice (Figure 2C). The
proportion of NK cells (CD3−/B220−/NKp46+), which
do not express FcRn (Supplementary Figure S2), was
significantly decreased in FcRn−/− mice (Figure 2H). As
well, the number of NK cells was altered but not significantly
(p = 0.059) in FcRn−/− mice (Figure 2P). The amount of
other cell types was not affected (Figures 2I,J,L–O), except
for neutrophils, which were increased in FcRn−/− mice
(Figure 2K).
Because the lungs are the main primary site of B16F10
nodules after intravenous injection, we explored whether
the cell modifications were also detected in other peripheral
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FIGURE 2 | Flow cytometry of leukocytes in lungs of WT (n = 8) and FcRn−/− (n = 8) mice injected, in the tail vein, with 1 × 105 B16-F10 tumor cells in 100 µl
medium. Lungs were excised and dissociated by combining mechanical dissociation with enzymatic degradation of the extracellular matrix to obtain a single-cell
suspension and cells were resuspended at 107 cells/ml in 1X PBS containing 5% FBS and 2mM EDTA for flow cytometry staining. Results correspond to the
proportion (top panel: A–H) and number (bottom panel: I–P) of (A,I) conventional dendritic cells, (B,J) macrophages/monocytes, (C,K) neutrophils, (D,L) B
lymphocytes, (E,M) T lymphocytes, (F,N) CD4T lymphocytes, (G,O) CD8T lymphocytes, and (H,P) natural killer (NK) cells (See Figure S1 for gating strategy). Data
are expressed as median ± Min to Max from one out of three independent experiments with similar results. ns = not significant, *p ≤ 0.05, **p ≤ 0.005, and ***p ≤
0.0001 using two-tailed non-parametric and unpaired Wilcoxon-Mann-Whitney test.
organs, such as the spleen, where no nodule was detected under
our experimental conditions. In the spleen, the percentage
and number of macrophages/monocytes (Figures 3B,J) and
neutrophils (Figures 3C,K) were significantly greater in
FcRn−/− than WT mice. There was no difference in percentage
and number of B lymphocytes (Figures 3D,L), T lymphocytes
(Figures 3E,M) and CD4+ T lymphocytes (Figures 3F,N). The
numbers of cDCs, CD8+ T lymphocytes and NK cells were
decreased in FcRn−/− mice (Figures 3I,O,P), with no variation
in proportion of these cells (Figures 3A,G,H). Altogether,
data obtained in this experimental lung metastasis model are
consistent with the implication of cDCs, CD8+ T lymphocytes
and NK cells in tumor development in FcRn−/− mice.
Lack of FcRn Affects NK Cell Maturation in
Experimental Lung Metastasis Model
To gain insight into defective NK cells in an FcRn-depleted
microenvironment, we explored NK cell maturation by flow
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FIGURE 3 | Flow cytometry of leukocytes in the spleen of WT (n = 5) and FcRn−/− (n = 5) mice injected, in the tail vein, with 1 × 105 B16F10 tumor cells in 100 µl
medium. Spleens were recovered and dissociated by combining mechanical dissociation with enzymatic degradation of the extracellular matrix to obtain a single-cell
suspension. Then, cells were resuspended at 107 cells/ml in 1X PBS containing 5% FBS and 2mM EDTA for flow cytometry staining. Results correspond to the
proportion (top panel: A–H) and number (bottom panel: I–P) of (A,I) conventional dendritic cells, (B,J) macrophages/monocytes, (C,K) neutrophils, (D,L) B
lymphocytes, (E,M) T lymphocytes, (F,N) CD4T lymphocytes, (G,O) CD8T lymphocytes, and (H,P) NK cells. Data are expressed as median ± Min to Max from one
of two independent experiments with similar results. ns = not significant, *p ≤ 0.05 and **p ≤ 0.005 using two-tailed non-parametric and unpaired
Wilcoxon-Mann-Whitney test.
cytometry on cell suspensions from lungs and spleen of
mice implanted with B16 cells. We distinguished the different
stages of NK-cell maturation as previously described under
physiological conditions (25, 26). In peripheral organs, mouse
NK-cell maturation proceeds through four stages based on
CD11b/CD27 expression: CD11b−/CD27− (double negative:
DN), CD11b−/CD27+ (CD11b−), CD11b+/CD27+ (double
positive: DP), and CD11b+/CD27− (CD27−). We analyzed
these different NK subtypes in lungs and spleen of mice
(Supplementary Figure S3). In lungs, the proportion of DN,
CD11b− and DP NK cells was significantly greater in FcRn−/−
thanWTmice, whereas that of CD27− NK cells, the moremature
NK stage, was significantly decreased (Figure 4A). The sum of
DN, CD11b−, and DP NK cells, corresponding to the less mature
cells, was 31.2 and 21.1% in FcRn−/− andWTmice, respectively.
Similarly, in spleen, the proportion of less mature cells DN NK
cells but not CD11b− and DP NK cells was greater in FcRn−/−
than WT mice. The proportion of CD27− NK cells was lower
in FcRn−/− than WT mice (Figure 4B). These results reveal less
mature NK cells in FcRn-deficient than WT mice in the B16F10
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FIGURE 4 | Flow cytometry of NK subtypes based on CD11b and CD27 markers in (A) lungs and (B) spleen from WT (n = 10) and FcRn−/− (n = 10) mice injected,
in the tail vein, with 1 × 105 B16F10 cells in 100 µl medium. Lungs and spleen were collected from euthanized animals and dissociated by combining mechanical
dissociation with enzymatic degradation of the extracellular matrix to obtain a single-cell suspension. Then, cells were resuspended at 107 cells/ml in 1X PBS
containing 5% FBS and 2mM EDTA for flow cytometry staining. Histograms represent the sum of the percentage of CD11b−/CD27−, CD11b−/CD27+ (CD11b−),
CD11b+/CD27+, and CD11b+/CD27− NK cell subtypes in WT and FcRn−/− mice. Data are means from two independent experiments. ns = not significant,
*p ≤ 0.05 using two-tailed non-parametric and unpaired Wilcoxon-Mann-Whitney test.
lung metastasis model, with a more pronounced effect in the
lungs.
NK Cell Development/Maturation Is
Impaired in FcRn−/− Naive Mice
To establish whether the defective NK cell maturation was
consecutive to B16F10 cell injection or pre-existed in FcRn−/−
mice, we phenotyped leukocytes by flow cytometry in naive
mice (Supplementary Figures S4, S5) and focused on NK-cell
sub-populations. First, the proportion of NK cells in lungs was
significantly lower in FcRn−/− than WT mice (Figure 5A), with
no difference in spleen (Figure 5B). Second, phenotype analysis
of NK cells revealed an organ-specific NK subtype distribution
previously described (27, 28) corresponding to an increased NK
DP population in lungs vs. spleen in bothWT and FcRn−/− mice
(Figures 5C,D). Third, the proportion of DN and CD11b− NK
cells, corresponding to more immature cells, was greater in lungs
and spleen of FcRn−/− than WT mice (31.8 vs. 18.8% in lungs
and 51.7 vs. 39.9% spleen). Altogether, these results suggest that
defective NK cell development/maturation was already present in
naive FcRn−/− mice.
To further investigate the origin of the impaired NK cell
maturation in an FcRn-depleted environment, we compared
NK-cell development in bone marrow of FcRn−/− and WT
mice. To distinguish the different stages of NK cell development
in bone marrow, we used specific markers as previously
described (29). The global level of NK cell precursors in bone
marrow did not differ between FcRn−/− and WT mice, as
characterized by CD122 expression, also known as interleukin-
2Rβ (Figure 6A). In contrast, the following stages of NK-cell
development were altered. The proportion of NK cells in stage
1 (CD122+/NK1.1−/NKp46−) was increased in FcRn−/− mice
and that of NK cells in stages 3, 4, and 5 was decreased as
compared with WT mice (Figures 6B,C). Our results clearly
indicate significantly impaired NK cell development in FcRn−/−
mice.
Defective Functions of NK Cells From
FcRn−/− Mice
We analyzed the ability of splenic NK cells from FcRn−/− and
WT naive mice to produce IFN-γ and degranulate, which are
major functions of NK cells. For this, we measured de novo
IFN-γ production by intracellular staining of NK cells and
NK cell degranulation by surface mobilization of CD107a, after
exogenous stimulation with PMA/ionomycine and cytokines (IL-
2 or IL-12, IL-15 and IL-18). Overall, NK cells from FcRn−/−mice
produced less IFN-γ (Figures 7A,C) and expressed less CD107a
on their surface (Figures 7B,D) than those from WT mice in all
conditions. To gain insight into NK function in FcRn−/− mice,
we assessed NK cell cytotoxicity against YAC-1 cells in basal
condition as described by Mizutani et al. (23). Although NK
cells from FcRn−/− animals had a significant lower expression
of CD107a compared to WT mice (Figure 7D), there was
no significant difference in NK cytoxicity against YAC-1 cells
(Figure 7E). This result suggests that NK cells from an FcRn−/−
deprived microenvironment displayed similar “basal” cytotoxic
properties when they are unstimulated. Additionally, we found
that NK cells from FcRn−/− and WT naive animals proliferated
identically (Figure 7F), but died more in the presence of IL-2
5,000 U/mL (Figure 7G). Altogether, our results indicate that NK
activation by cytokines is impaired in FcRn−/− naive mice.
DISCUSSION
Herein, we confirmed the crucial role of FcRn in the anti-
tumor immune response in the B16F10 model of experimental
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FIGURE 5 | Flow cytometry of NK cell proportion in (A) lungs and (B) spleen from WT (n = 13) and FcRn−/− (n = 12) naive mice. Data are expressed as median ±
Min to Max from two independent experiments. Flow cytometry of NK subtypes based on CD11b and CD27 markers in (C) lungs and (D) spleen from WT (n = 5) and
FcRn−/− (n = 5) naive mice. After euthanasia of naive animals, lungs and spleen were collected and dissociated by combining mechanical dissociation with
enzymatic degradation of the extracellular matrix to obtain a single-cell suspension. Then, cells were resuspended at 107 cells/ml in 1X PBS containing 5% FBS and
2mM EDTA for flow cytometry staining. Histograms represent the sum of the percentage of CD11b−/CD27−, CD11b−/CD27+ (CD11b−), CD11b+/CD27+, and
CD11b+/CD27− NK cell subtypes in WT and FcRn−/− mice. Data are means from one experiment. ns = not significant, *p ≤ 0.05, **p ≤ 0.005 using two-tailed
non-parametric and unpaired Wilcoxon-Mann-Whitney test.
FIGURE 6 | Flow cytometry of NK cell development in bone marrow of WT (n = 5) and FcRn−/− (n = 5) naive mice. After euthanasia of naive animals, bone-marrow
cells were isolated from the femur and tibia and cells separated by mechanical dissociation. Then, cells were resuspended at 107 cells/ml in 1X PBS containing 5%
FBS and 2mM EDTA for flow cytometry staining. The development of NK cells is initiated with the expression of (A) CD122, then three early immature steps [NK
precursor (NKP), stage 1 and stage 2] are identified with the expression of (B) CD122, NK1,1 and NKp46. (C) From stage 2, stage 5 and 6 subtypes are characterized
by CD49b and CD11b expression. Acquisition of marker during NK cell development is represented schematically by arrows under the graphics. Data are expressed
as median ± Min to Max from one out of two independent experiments with similar results. ns = not significant and *p ≤ 0.05 using two-tailed non-parametric and
unpaired Wilcoxon-Mann-Whitney test.
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FIGURE 7 | Influence of FcRn on NK cell functions and in vitro expansion. Purified splenic NK cells were analyzed by flow cytometry for (A) the intracellular
measurement of IFN-γ and (B) the surface expression of the late endosomal marker CD107a, after 4-h incubation at 37◦C without (Ctr) or with PMA
(100 ng/mL)/ionomycine (500 ng/mL). Data are median ± Min to Max analyzed from eight independent experiments using pooled NK cells from 2 mice. Freshly
isolated splenocytes were seeded in RMPI 1640 complete medium supplemented with 5,000 U/ml rhIL2 or with 5 ng/ml rhIL12, 50 ng/ml rhIL15, and 10 ng/ml rhIL18
for 4-h (C,D). Within splenocytes, CD3−/NK1.1+/NKp46+ cells were analyzed for (C) the intracellular expression of IFN-γ and (D) the surface expression of CD107a
by flow cytometry. Data are median ± Min to Max from two independent experiments using pooled spleens from 2 mice. (E) Cytotoxicity assay was performed against
CFSE-labeled YAC-1 target cells with different ratios of purified NK cells previously maintained overnight in RPMI 1640 complete medium supplemented with 50 U/ml
of rhIL2 (n = 3). The results were expressed as means ± SEM. (F,G) Purified splenic NK cells were plated in complete medium supplemented with 5,000 U/ml rhIL2.
(F) The living cell numbers and (G) the percentage of dead cells were determined daily by manual cell counting using trypan blue in Malassez chamber (n = 3). The
results were expressed as mean ± SEM (F) and median ± Min to Max (G). ns = not significant *p ≤ 0.05 and **p ≤ 0.005 using two-tailed non-parametric and
unpaired Wilcoxon-Mann-Whitney test.
lung metastasis in which we clearly show an increase in lung
metastasis in an FcRn-depleted environment in mice. Analysis of
the immune cells infiltrating the lungs after intravenous injection
of B16F10 cells revealed a decreased proportion of cDCs and
CD8T lymphocytes with lack of FcRn. These results agree with
the already assessed function of FcRn-mediated tumor protection
driven by DC and CD8+ T-cell activities described by Baker et al.
(12). However, we identified NK cells as a new and additional
cellular component of the FcRn-dependent anti-tumor response.
NK cells are effector lymphoid cells belonging to the innate
immune system that can recognize and kill microbial-infected
cells and play an important role in the immune surveillance
against tumors (30). In this study, mice lacking FcRn showed
reduced intratumoral NK-cell infiltration, which may participate
in amplified development of B16F10 lung lesions, because NK
cells are required for B16F10 tumor rejection (16, 23). In
FcRn−/− mice, NK cells had an immature phenotype on the
whole, as characterized by surface markers (26). The particular
cells affected were DP and CD27− NK subtypes, which are able
to proliferate under inflammation and exhibit effector functions.
The distribution of the four maturation stages depends on
the tissue (31). In our B16F10 experimental lung metastasis
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model, the distribution of the NK cell subtypes was modified
in lungs of FcRn−/− mice and in the spleen to a lesser
extent. These results suggest that the phenotypic alteration
of NK cells is more pronounced in tumor-associated tissues.
The alteration may be due to impaired in situ maturation
in the tumor lung microenvironment caused by tumor-related
soluble factors (32, 33). To understand the origin of the NK
cell immature phenotype, we evaluated the distribution of NK
cell subtypes in FcRn−/− naive mice and found that they also
displayed an immature phenotype in lungs as well as spleens.
Although NK sub-populations are distributed differently in the
spleen and lungs of mice (28) because of distinct homing
properties and tissue-specific maturation, their distribution in
the different peripheral organs of FcRn−/− mice is unusual.
Because NK cells develop from lineage-restricted progenitors
in bone marrow, we analyzed NK subpopulations in this
compartment. The proportion of NK precursors was higher in
FcRn−/− than WT mice, which suggests partial blockade of NK-
cell development at early steps. This phenomenon confirmed the
previously described hindrance effect of tumor growth on NK-
cell maturation in bone marrow (17, 34) that we also observed in
our lung experimental metastasis model in WT mice.
Because altered NK-cell maturation would affect the cellular
properties of NK cells, we analyzed the ability of NK cells
to synthesize IFN-γ and mobilize CD107a, which reflects NK-
cell degranulation/cytotoxic activity. NK cells help eliminate
B16F10 tumor cells in the experimental model of lung metastasis
(16) and effector molecules, such as perforin and IFN-γ play
important roles in NK-mediated inhibition of metastasis and
tumor growth (17, 35). Although, non-activated NK cells from
FcRn−/− animals had a significant lower expression of CD107a
compared to WT mice, it was not correlated with a reduced
cytotoxicity efficacy. Interestingly, NK cells from FcRn−/− mice
were less prone to degranulate and synthesize IFN-γ after
chemical stimulation and (IL-2 or IL-12, IL-15 and IL-18)
cytokine activation thanNK cells fromWTmice. These cytokines
are involved in proliferation, differentiation/maturation of NK
cells and enhance their effector functions (36, 37). Pre-activation
of NK cells with IL-2 or IL-12, IL-15 and IL-18 results in the
generation of NK cells efficient to target and kill tumor cells
(24, 38). The lower expression of CD107a and IFN-γ synthesis
(after IL-2 or IL-12, IL-15, and IL-18 activation) as well as the
increased cell death (in the presence of IL-2) in FcRn−/− NK
cells, support an impaired response of NK cells to cytokines in
an FcRn−/− deprived microenvironment. This might be critical
to limit the spreading of lung tumor lesions in the B16F10 lung
metastasis model. Accordingly, a lower CD107a expression was
found in splenic NK cells from FcRn−/− animals (compared
to WT mice) in the B16F10 model and which persisted after
cytokine activation (Supplemental Figure S6).
Once activated, NK cells produce cytokines and chemokines
that regulate both the innate and adaptive immune system (39,
40). Because NK cells express no FcRn, the immature phenotype
of NK cells might arise via indirect mechanisms due to the
absence of FcRn in other cells of the immune system, such as DCs
(10). Previous studies described interactions between NK cells
and DCs and found a bidirectional crosstalk leading to NK-cell
priming by DCs, which in turn induces DC maturation (41, 42).
Knowing that FcRn-positive DCs are important for shaping the
CD8+ effector T-cell anti-tumor response (12), FcRn might also
affect the bidirectional cross-talk between NK cells and DCs. In
light of our results showing impaired secretion of IFN-γ by NK
cells in FcRn−/− mice and the important role of IFN-γ in DC
maturation by NK cells (43), IFN-γ might play a role in an FcRn-
dependent cross-talk between NK cells and DC. Following this
idea, the defective interleukin-12 level described in FcRn−/− DCs
(12) may also participate in the impaired NK-cell activation in
ourmodel because of its involvement in IFN-γ production by NK
cells (41). Other FcRn-expressing cells, such as neutrophils and
monocytes/macrophages (10, 44) may also be involved in NK-
cell interactions (40, 45). Of note, we found a marked increase in
the proportion of neutrophils in FcRn−/−mice as compared with
WT mice. Similarly, the proportion of neutrophils was enhanced
in the model of anti-TNF antibody immunization in FcRn-
deficientmice (46) and in othermodels (47). Previous studies also
reported a high number of intratumoral neutrophils associated
with the induction and maintenance of tumor angiogenesis
(48, 49). Moreover, in breast cancer (50) and diverse murine
cancer models (51, 52), macrophage/monocyte cells (53, 54)
and/or neutrophils (52, 55) have been implicated in tumor
promotion. From this evidence and our results, we cannot rule
out a link between neutrophils expressing FcRn (44) and NK-
cell maturation/activation. Whether this potential interaction
occurred via soluble factors, such as cytokines or direct cell
contact needs to be investigated. Finally, several cell types present
in the hematopoietic niche or secondary lymphoid organs express
FcRn. This is the case with stromal cells, endothelial and epithelial
cells (44), which may also intervene in NK-cell maturation (36,
40, 56, 57). Further studies are needed to decipher the impact of
FcRn-positive cells in the maturation of NK precursors.
For the first time, we described that NK-cell mediated
tumor elimination/surveillance is impaired in an FcRn-deficient
microenvironment. This could be linked to an abnormal
cytokine response which needs further investigations to provide
understanding in the involvement of FcRn. In light of our
previous results (13) and those from Baker et al. (12), showing
FcRn dysregulation in lung and colorectal cancers and associated
with an unfavorable outcome, our current findings further
support the central role of FcRn in anti-tumor immunity and
highlight the interest of targeting FcRn for therapeutic purposes.
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